$3.240
+0.072 (+2.21%)收盤時
價格預測
在 App 中開啟以解鎖更長週期的預測。
XFOR 相似圖表分析預測
Alphio's XFOR stock price prediction model matches the current X4 Pharmaceuticals Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $3.27 (+0.96%). The 1-week path is $3.21 (-0.87%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
該買進 X4 Pharmaceuticals Inc 股票嗎？
X4 Pharmaceuticals Inc is a good buy right now due to its recent positive earnings report showing a revenue increase of 347.2% year-over-year, with a current price of $3.35 significantly below the analyst target of $12. Additionally, the RSI is at 78.67, indicating strong momentum. The main risk is the upcoming earnings report, with an estimated EPS of -0.19, which could impact investor sentiment.
XFOR 股價於 Wednesday 收在 $3.24，此前上漲 +2.21%
X4 Pharmaceuticals Inc (XFOR) last closed at $3.24, gaining +2.21%. These facts feed the 1-day and 1-week XFOR price prediction above.
預測驅動因素
X4 Pharmaceuticals Inc（XFOR）的預測驅動因素綜合了相似的圖表形態、季節性與移動平均線。
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bullish
SMA 200
Bearish
相似圖表形態
近期走勢與 XFOR 最接近的股票，依相似度排序。
XFOR 季節性分析
Historically the probability of a positive November return for XFOR is 0.00%. April offers the highest probability of a positive month at 65.62%, while October is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
相關文章
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
- AppLovin Q3 2026 Deep Dive: Beaten-Down S&P Dog Meets Axon Next-Gen Beat-and-Raise—and a $3.2B BuybaAppLovin Q3 2026: $2.185B rev (+55%), EPS $4.30 vs ~$4.03–4.04 Street, Adj EBITDA $1.842B (84%). Beat own guide $100M; Q4 $2.365–2.395B; auth +$3.2B; AH +22–24%.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。